Assessing the prevalence of EBV in pediatric leukemia patients compared to healthy controls by serology | ||||
Microbes and Infectious Diseases | ||||
Articles in Press, Accepted Manuscript, Available Online from 08 July 2025 | ||||
Document Type: Original Article | ||||
DOI: 10.21608/mid.2025.396354.2928 | ||||
![]() | ||||
Authors | ||||
Zahraa Talib Ahbail ![]() | ||||
College of Medicine, University of AL-Iraqia, Baghdad, Iraq | ||||
Abstract | ||||
Background: The Epstein-Barr virus (EBV) is specifically associated with certain human cancers, including lymphoproliferative disorders. The virus has been implicated in the dysregulation of immune responses and the activation of oncogenic pathways, which may play a role in leukemogenesis, particularly in genetically susceptible individuals. Objectives: Explore the relationship between EBV exposure, as measured by Immunoglobulin G (IgG) antibodies, and the incidence of leukemia in pediatric patients. Methods: 100 blood samples were collected. The age distribution of the patients ranged from 1 to 13 years. Enzyme-linked immunosorbent assay (ELISA)technology identified the presence of EBV infection. The samples were centrifuged, separated, and stored at 4°C until the detection tests for EBV-(IgG) were conducted. Results: The mean level of the viral parameter of Epstein–Barr virus Immunoglobulin-G (EBV-IgG) was significantly higher among the cases group (leukemic children) than that of the control group with a significant difference of -0.558500 (t= -15.988, df:98, P= 0.000) respectively. Conclusion: The present findings illustrate the importance of accounting for viral cofactors, such as EBV, in the etiology of juvenile leukemia. Future studies are needed to investigate how EBV might cause juvenile leukemia and to find out if it can be used as an early warning sign or a target for treatment. | ||||
Keywords | ||||
Pediatric; leukemia; Epstein-Barr virus | ||||
Statistics Article View: 60 |
||||